Myriam Chalabi’s highlights from ESMO24

The ESMO Congress 2024 (ESMO24) is one of the most globally influential platforms in oncology, bringing together clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from across the world.

Held from 13-17 September 2024, in Barcelona and through a Virtual Congress Platform, ESMO24 will serve as a critical hub for the dissemination of the latest cutting-edge cancer research, offering high-quality education and dynamic networking opportunities.

In connection to that, Myriam Chalabi shared several valuable posts from ESMO24 on her X account:

Manon de Graaf at NKI Reveals Insights on Stage 1 TNBC Using IKNL Registries

“Young talent Manon de Graaf from The Netherlands Cancer Institute (NKI) MarleenKokLab presenting data on patients with stage 1 TNBC.

Good registries to IKNL allow for analysis of populations excluded from most trials!”

Lower GI Session: NICHE2 & NICHE3 Presentations

“Ready for the lower GI Proffered Paper session with back-to-back presentations of NICHE2 and NICHE3″

John Haanen Receives Lifetime Achievement Award for Cancer Immunotherapy

“Lifetime achievement award for John Haanen. A fantastic person, mentor and researcher, leading the way for cancer immunotherapy across tumor types at The Netherlands Cancer Institute (NKI) and beyond.

So so well-deserved”

Rebecca Dent’s Welcome: Global Contributions and Awards Preview

“Welcome by Rebecca Dent on the power of contribution across the globe, and providing a preview of what is to come in the presidential sessions.

Now on to the awards!”

“During the ESMO24 opening ceremony Rebecca Dent encouraged us to attend sessions beyond our normal path and in the Barcelona auditorium, the breast mini-oral session!”

Young Oncologists Shine in ESMO24 Breast Mini-Orals

“Young oncologists were killing it in the breast mini-orals session ESMO24. Shoutout to all established investigators: give them the stage and they won’t disappoint!”

Metastatic Breast Session: MarleenKokLab’s TripleB Study

“Right now: metastatic breast proffered oral session. MarleenKokLab presenting the tripleB study in TNBC.”

Dr. Myriam Chalabi, a medical oncologist and researcher based at the Netherlands Cancer Institute, specializes in gastrointestinal tract cancer. Her research primarily focuses on immunotherapy for gastrointestinal cancers. In 2017, she initiated a clinical investigation called the NICHE trial, aiming to explore the potential benefits of immunotherapy for early-stage colon cancer patients.

Through this trial, Dr. Chalabi identified a subtype of colon cancer patients deficient in mismatch repair, exhibiting DNA replication errors, who demonstrate remarkable responsiveness to immunotherapy. She possesses expertise in neoadjuvant immunotherapies for these specific indications. Additionally, Dr. Chalabi underscores the significance of biomarkers in patient selection for immuno-oncology clinical trials.

For more latest updates from ESMO24, follow OncoDaily.